[Federal Register Volume 61, Number 64 (Tuesday, April 2, 1996)]
[Notices]
[Page 14563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-7895]



-----------------------------------------------------------------------


DEPARTMENT OF DEFENSE

Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Diagnosis of, and a 
Vaccine Against, Dengue Virus

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability of U.S. Patent Application Serial No. 08/504,878 entitled 
``Recombinant Vaccine Against Dengue Virus'', filed July 20, 1995, for 
licensing. This patent has been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.

FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney, 
(301) 619-2065 or telefax (301) 619-7714.

SUPPLEMENTARY INFORMATION: The invention describes methods of 
production and purification of recombinant dengue virus envelope 
proteins for use as diagnostic reagents or as vaccines and, when 
combined, as a multivalent vaccine against all four dengue virus 
serotypes. Each recombinant envelope protein was expressed by 
baculovirus in insect cells and formed a particle which was purified. 
This purification process consists of sonication of cell lysates and 
differential centrifugations. Native antigenic and immunogenic 
properties are maintained in the purified product. The vaccine is 
designed for administration by subcutaneous, intramuscular or other 
suitable routes or without adjuvant.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-7895 Filed 4-1-96; 8:45 am]
BILLING CODE 3710-08-M